OncoCyte Price to Sales Ratio 2014-2023 | OCX
Historical PS ratio values for OncoCyte (OCX) over the last 10 years. The current P/S ratio for OncoCyte as of April 30, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| OncoCyte P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2024-05-01 | 2.55 | 12.75 | |
| 2023-12-31 | 2.50 | $0.20 | 12.50 |
| 2023-09-30 | 3.12 | $0.21 | 14.97 |
| 2023-06-30 | 4.60 | $0.17 | 27.41 |
| 2023-03-31 | 7.09 | $0.15 | 46.48 |
| 2022-12-31 | 6.42 | $0.19 | 34.68 |
| 2022-09-30 | 14.60 | $-0.30 | 0.00 |
| 2022-06-30 | 17.99 | $-0.10 | 0.00 |
| 2022-03-31 | 29.80 | $0.31 | 95.04 |
| 2021-12-31 | 43.40 | $0.50 | 85.96 |
| 2021-09-30 | 71.20 | $1.09 | 65.05 |
| 2021-06-30 | 114.80 | $1.04 | 109.91 |
| 2021-03-31 | 103.80 | $0.64 | 163.32 |
| 2020-12-31 | 47.80 | $0.37 | 130.23 |
| 2020-09-30 | 27.80 | $0.21 | 130.08 |
| 2020-06-30 | 38.20 | $0.05 | 785.21 |
| 2020-03-31 | 49.00 | $0.01 | 0.00 |
| 2019-12-31 | 45.00 | 0 | 0.00 |
| 2019-09-30 | 42.00 | 0 | 0.00 |
| 2019-06-30 | 49.80 | 0 | 0.00 |
| 2019-03-31 | 79.00 | 0 | 0.00 |
| 2018-12-31 | 27.60 | 0 | 0.00 |
| 2018-09-30 | 50.00 | 0 | 0.00 |
| 2018-06-30 | 51.00 | 0 | 0.00 |
| 2018-03-31 | 42.00 | 0 | 0.00 |
| 2017-12-31 | 93.00 | 0 | 0.00 |
| 2017-09-30 | 151.00 | 0 | 0.00 |
| 2017-06-30 | 104.00 | 0 | 0.00 |
| 2017-03-31 | 119.00 | 0 | 0.00 |
| 2016-12-31 | 141.00 | 0 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.021B | $0.002B |
| OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $122.851B | 15.41 |
| Cencora (COR) | United States | $47.686B | 19.03 |
| ICON (ICLR) | Ireland | $24.574B | 23.20 |
| DiDi Global (DIDIY) | China | $24.011B | 0.00 |
| Avantor (AVTR) | United States | $16.459B | 24.23 |
| Viatris (VTRS) | United States | $13.776B | 3.96 |
| CochLear (CHEOY) | Australia | $13.705B | 0.00 |
| Revvity (RVTY) | United States | $12.658B | 22.18 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.086B | 0.00 |
| Medpace Holdings (MEDP) | United States | $12.032B | 39.59 |
| Charles River Laboratories (CRL) | United States | $11.796B | 21.50 |
| Natera (NTRA) | United States | $11.354B | 0.00 |
| Solventum (SOLV) | United States | $11.215B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.201B | 0.00 |
| HealthEquity (HQY) | United States | $6.770B | 50.58 |
| Bausch + Lomb (BLCO) | Canada | $5.109B | 19.65 |
| Organon (OGN) | United States | $4.786B | 4.61 |
| Doximity (DOCS) | United States | $4.531B | 33.74 |
| PACS (PACS) | United States | $3.749B | 0.00 |
| Surgery Partners (SGRY) | United States | $3.171B | 29.35 |
| Sotera Health (SHC) | United States | $3.170B | 15.56 |
| Progyny (PGNY) | United States | $3.081B | 51.71 |
| GoodRx Holdings (GDRX) | United States | $2.804B | 142.00 |
| Life Times (LTH) | United States | $2.687B | 29.70 |
| Premier (PINC) | United States | $2.502B | 9.16 |
| AMN Healthcare Services Inc (AMN) | United States | $2.273B | 7.35 |
| Agilon Health (AGL) | United States | $2.261B | 0.00 |
| Teladoc Health (TDOC) | United States | $2.162B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $1.830B | 0.00 |
| Agiliti (AGTI) | United States | $1.381B | 22.56 |
| Establishment Labs Holdings (ESTA) | $1.373B | 0.00 | |
| NovoCure (NVCR) | Jersey | $1.317B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $0.982B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.745B | 7.71 |
| Embecta (EMBC) | United States | $0.583B | 3.85 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.531B | 0.00 |
| Enhabit (EHAB) | United States | $0.506B | 45.86 |
| Auna S.A (AUNA) | Luxembourg | $0.503B | 0.00 |
| LifeMD (LFMD) | United States | $0.488B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.482B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.445B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.437B | 0.00 |
| MultiPlan (MPLN) | United States | $0.419B | 0.00 |
| CareDx (CDNA) | United States | $0.402B | 0.00 |
| Beauty Health (SKIN) | United States | $0.399B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.379B | 0.00 |
| DocGo (DCGO) | United States | $0.352B | 56.33 |
| ModivCare (MODV) | United States | $0.333B | 4.42 |
| Ascend Wellness Holdings (AAWH) | United States | $0.304B | 0.00 |
| Sharecare (SHCR) | United States | $0.259B | 0.00 |
| Biodesix (BDSX) | United States | $0.142B | 0.00 |
| So-Young (SY) | China | $0.129B | 43.33 |
| Oncology Institute (TOI) | United States | $0.079B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.071B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.054B | 0.00 |
| NeueHealth (NEUE) | United States | $0.052B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.036B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.036B | 0.00 |
| Nutex Health (NUTX) | United States | $0.030B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.030B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| DermTech (DMTK) | United States | $0.021B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.014B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.014B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
| TRxADE HEALTH (MEDS) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.007B | 0.00 |
| OpGen (OPGN) | United States | $0.005B | 0.00 |
| Assure Holdings (IONM) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |